Marc Engelen received his MD from the University of Amsterdam, the Netherlands in 2002. He was trained as a neurologist and subsequently subspecialized in pediatric neurology at the Academic Medical Center (AMC), also in Amsterdam. In 2012, Dr. Engelen obtained a PhD on “Translational studies in Adrenoleukodystrophy”. He is currently a member of the medical staff of the Departments of Neurology and the Department of Pediatrics at AMC and has a special interest in peroxisomal disorders. In 2015, the AMC was designated the national expert center for this group of diseases. His research focuses on adrenoleukodystrophy and in 2014 he received a Veni grant from NWO (Netherlands Organization for Scientific Research) to study the natural history of adrenoleukodystrophy and identify predictive biomarkers for the onset of cerebral adrenoleukodystrophy.
Rachel Salzman serves as Chief Scientific Officer of The Stop ALD Foundation (SALD), and has held this position since 2001. SALD is a non-profit Medical Research Organization dedicated to employing entrepreneurial approaches and innovative methodology towards effective therapies, cures, and prevention of adrenoleukodystrophy. The biomedical interests of the Foundation include gene therapy, hematopoietic stem cells, mesenchymal and other adult stem cells, genomics, and small molecules. Rachel also consults for large pharma and biotech in the field of drug development, including preclinical and clinical analysis in a variety of therapeutic areas. This consultancy includes advising veterinary pharmaceutical developers and food production industry on nutritional supplements, preventive healthcare, and animal housing conditions/other welfare practices. Prior to these roles, Rachel worked in private veterinary practice in both large and small animal medicine for over 10 years. She has a D.V.M. from Oklahoma State University and a B.S. from Rutgers University.
Stephan Kemp is an associate professor and Principal Investigator at the Department of Genetic Metabolic Diseases / Pediatrics at the Academic Medical Center (AMC), University of Amsterdam, the Netherlands. Dr. Kemp was trained as a translational researcher at Johns Hopkins University/ Kennedy Krieger Institute, Baltimore, Maryland, USA and obtained his PhD in 1999 at the University of Amsterdam. He has more >20 years of experience with adrenoleukodystrophy research and published >80 papers and book chapters on adrenoleukodystrophy. In 1999, together with Dr. Hugo Moser, he initiated the ALD database (www.x-ald.nl), which moved to www.adrenoleukodystrophy.info in 2017. He is chairman of the European Adrenomyeloneuropathy board, scientific advisor of the Dutch ALD patient organization and the Stop ALD Foundation and a member of the board of directors of ALD Connect. In 2015, he received the AMC Societal Impact Award (ASIA). His research focuses on lipid metabolism and neurotoxicity.
Last modified | 2018-03-19